



Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006,235704 Fax : +91-8532-235876

E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

SML/146/10-11

Date:06/09/2010

To,
National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G-Block,
Bandra- Kurla Complex,
Bandra (E)
Mumbai 400051.

Reg: GMP Certificate

Ref: Symbol: SHILPAMED, Series: EQ.

We are pleased to inform you that our Company has been granted certificate of GMP Compliance from TGA Australia.

We are herewith enclosing the copy of certificate for your information.

Thanking you,

Yours faithfully
For SHILPA MEDICARE LIMITED

RAMAKANT INNANI
(COMPLIANCE OFFICER)



Encl: As Above.



Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs.

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)

Phone : +91-8532-235006, 235704 FAX : +91-8532-235876

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

Dated: 6th Sept. 2010

THERAPEUTIC GOODS ADMINISTRATION (TGA) AUSTRALIA APPROVES SHILPA MEDICARE MANUFACTURING FACILITY FOR GMP

The Department of Health and Ageing, Therapeutic Goods Administration (TGA) Australia has approved the manufacturing facility of Shilpa Medicare Ltd located at Deosugur Industrial Area for Good Manufacturing Practice (GMP) for active Pharmaceutical Ingredients.

The Oncology Manufacturing facility of Shilpa Medicare Ltd has been audited by TGA and found compliance with the requirement of the ICH Harmonized Tripartite guideline Good Manufacturing Practice Guide for API's.

This is another important Milestone for Shilpa in its Journey to be a global Oncology API Company.

For SHILPA MEDICARE LTD

**B.VISHNUKANT
MANAGING DIRECTOR**



POSSESSES G.M.P. CERTIFICATE AS PER WORLD HEALTH ORGANISATION SPECIFICATION



GMP CERTIFICATE OF MANUFACTURING FACILITY

No. MI-23092008-CE-001542-11

Shilpa Medicare Limited of Plots 1A-7A Deosugur Industrial Area,
Deosugur Raichur, Karnataka 584 170, India has been subject to audit by
the Office of Manufacturing Quality, Therapeutic Goods Administration.

From the knowledge gained during the last audit, which was conducted on
11-13 March 2010, it is considered that the company complies with the
requirements of the ICH Harmonised Tripartite Guideline Good
Manufacturing Practice Guide for Active Pharmaceutical Ingredients.

The company manufactures the active pharmaceutical ingredients;
gemcitabine hydrochloride, oxaliplatin, irinotecan and temozolamide.

This certificate remains valid, provided that re-audits are conducted when
scheduled by the TGA.

The validity of the certificate may be checked by contacting the
undersigned.

Expiry Date: 13 May 2012

Date: 24/08/2010

Michel Lok
Head of Office
Office of Manufacturing Quality
PO Box 100, Woden ACT 2606, Australia
Tel: +61 (0)2 6232 8622
Fax: +61 (0)2 6232 8426

